Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Article in English | MEDLINE | ID: mdl-31244444

ABSTRACT

Leukemia is a group of progressive hematologic malignancies derived from stem cells in bone marrow which causes a large number of cancer deaths. Even with treatment such as traditional chemotherapy, targeted therapy, and allogeneic stem cell transplantation (allo-HSCT), many patients suffer from relapse/refractory disease, and the overall survival is dismal. Leukemic stem cells (LSCs) are induced by gene mutations and undergo an aberrant and poorly regulated proliferation process which is involved in the evolution, relapse, and drug-resistance of leukemia. Emerging studies demonstrate that CD123, the interleukin 3 receptor alpha (IL-3Rα), is highly expressed in LSCs, while not normal hematopoietic stem cells (HSCs), and associates with treatment response, minimal residual disease (MRD) detection and prognosis. Furthermore, CD123 is an important marker for the identification and targeting of LSCs for refractory or relapsed leukemia. Anti-CD123 target-therapies in pre-clinical studies and clinical trials confirm the utility of anti-CD123 neutralizing antibody-drugs, CD3×CD123 bispecific antibodies, dual-affinity retargeting (DART), and anti-CD123 chimeric antigen receptor-modified T-cell (CAR-T) therapies in progress. This review summarizes the most recent progress on the study of CD123 biology and the development of novel CD123-targeted therapies.


Subject(s)
Antineoplastic Agents, Immunological/therapeutic use , Interleukin-3 Receptor alpha Subunit/analysis , Leukemia/diagnosis , Leukemia/therapy , Animals , Biomarkers, Tumor/analysis , Biomarkers, Tumor/antagonists & inhibitors , Humans , Immunotherapy, Adoptive , Interleukin-3 Receptor alpha Subunit/antagonists & inhibitors
2.
Epigenetics ; 11(11): 804-818, 2016 Nov.
Article in English | MEDLINE | ID: mdl-27611852

ABSTRACT

Wilson disease (WD), a genetic disorder affecting copper transport, is characterized by hepatic and neurological manifestations with variable and often unpredictable presentation. Global DNA methylation in liver was previously modified by dietary choline in tx-j mice, a spontaneous mutant model of WD. We therefore hypothesized that the WD phenotype and hepatic gene expression of tx-j offspring could be modified by maternal methyl supplementation during pregnancy. In an initial experiment, female tx-j mice or wild type mice were fed control or choline-supplemented diets 2 weeks prior to mating through embryonic day 17. Transcriptomic analysis (RNA-seq) on embryonic livers revealed tx-j-specific differences in genes related to oxidative phosphorylation, mitochondrial dysfunction, and the neurological disorders Huntington's disease and Alzheimer disease. Maternal choline supplementation restored the transcript levels of a subset of genes to wild type levels. In a separate experiment, a group of tx-j offspring continued to receive choline-supplemented or control diets, with or without the copper chelator penicillamine (PCA) for 12 weeks until 24 weeks of age. Combined choline supplementation and PCA treatment of 24-week-old tx-j mice was associated with increased liver transcript levels of methionine metabolism and oxidative phosphorylation-related genes. Sex differences in gene expression within each treatment group were also observed. These results demonstrate that the transcriptional changes in oxidative phosphorylation and methionine metabolism genes in WD that originate during fetal life are, in part, prevented by prenatal maternal choline supplementation, a finding with potential relevance to preventive treatments of WD.


Subject(s)
DNA Methylation/genetics , Epigenomics , Hepatolenticular Degeneration/genetics , Transcriptome/genetics , Animals , Choline/administration & dosage , Choline/metabolism , Copper/metabolism , Dietary Supplements , Disease Models, Animal , Female , Gene Expression Regulation/drug effects , Hepatolenticular Degeneration/metabolism , Hepatolenticular Degeneration/pathology , Humans , Liver/metabolism , Liver/pathology , Methionine/metabolism , Mice , Oxidative Phosphorylation/drug effects , Penicillamine/administration & dosage , Pregnancy
3.
Eur J Immunol ; 46(9): 2155-61, 2016 09.
Article in English | MEDLINE | ID: mdl-27325567

ABSTRACT

Thymic stromal lymphopoietin (TSLP) and IL-7 are cytokines that signal via the IL-7 receptor alpha (IL-7Rα) to exert both overlapping and unique functions during early stages of mouse B-cell development. In human B lymphopoiesis, the requirement for IL-7Rα signaling is controversial and the roles of IL-7 and TSLP are less clear. Here, we evaluated human B-cell production using novel in vitro and xenograft models of human B-cell development that provide selective IL-7 and human TSLP (hTSLP) stimulation. We show that in vitro human B-cell production is almost completely blocked in the absence of IL-7Rα stimulation, and that either TSLP or IL-7 can provide a signal critical for the production and proliferation of human CD19(+) PAX5(+) pro-B cells. Analysis of primary human bone marrow stromal cells shows that they express both IL-7 and TSLP, providing an in vivo source of these cytokines. We further show that the in vivo production of human pro-B cells under the influence of mouse IL-7 in a xenograft scenario is reduced by anti-IL-7 neutralizing antibodies, and that this loss can be restored by hTSLP at physiological levels. These data establish the importance of IL-7Rα mediated signals for normal human B-cell production.


Subject(s)
B-Lymphocytes/cytology , B-Lymphocytes/metabolism , Cytokines/metabolism , Interleukin-7/metabolism , Lymphopoiesis , Receptors, Interleukin-7/metabolism , Signal Transduction , Animals , B-Lymphocytes/drug effects , B-Lymphocytes/immunology , Cells, Cultured , Cytokines/pharmacology , Gene Expression , Humans , Interleukin-7/pharmacology , Lymphopoiesis/drug effects , Lymphopoiesis/immunology , Mesenchymal Stem Cells/metabolism , Mice , Mice, Transgenic , Precursor Cells, B-Lymphoid/cytology , Precursor Cells, B-Lymphoid/drug effects , Precursor Cells, B-Lymphoid/metabolism , Signal Transduction/drug effects , Thymic Stromal Lymphopoietin
4.
Metab Syndr Relat Disord ; 14(4): 202-9, 2016 May.
Article in English | MEDLINE | ID: mdl-26881897

ABSTRACT

BACKGROUND: Previous studies indicated that nonpurified and purified commercially available control murine diets have different metabolic effects with potential consequences on hepatic methionine metabolism and liver histology. METHODS: We compared the metabolic and histological effects of commercial nonpurified (13% calories from fat; 57% calories from carbohydrates with 38 grams/kg of sucrose) and purified control diets (12% calories from fat; 69% calories from carbohydrates with ∼500 grams/kg of sucrose) with or without choline supplementation administered to C3H mice with normal lipid and methionine metabolism. Diets were started 2 weeks before mating, continued through pregnancy and lactation, and continued in offspring until 24 weeks of age when we collected plasma and liver tissue to study methionine and lipid metabolism. RESULTS: Compared to mice fed nonpurified diets, the liver/body weight ratio was significantly higher in mice fed either purified diet, which was associated with hepatic steatosis and inflammation. Plasma alanine aminotransferase levels were higher in mice receiving the purified diets. The hepatic S-adenosylmethionine (SAM)/S-adenosylhomocysteine (SAH) ratio was higher in female mice fed purified compared to nonpurified diet (4.6 ± 2 vs. 2.8 ± 1.9; P < 0.05). Choline supplementation was associated with improvement of some parameters of lipid and methionine metabolism in mice fed purified diets. CONCLUSIONS: Standard nonpurified and purified diets have significantly different effects on development of steatosis in control mice. These findings can help in development of animal models of fatty liver and in choosing appropriate laboratory control diets for control animals.


Subject(s)
Choline/metabolism , Fatty Liver/metabolism , Lipid Metabolism , Methionine/metabolism , Animals , Diet , Dietary Fats/administration & dosage , Dietary Sucrose/administration & dosage , Dietary Supplements , Feeding Behavior , Female , Liver/metabolism , Mice , Mice, Inbred C3H , S-Adenosylhomocysteine/metabolism , S-Adenosylmethionine/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...